SAB BIOTHERAPEUTICS, INC. Operating Expenses
SAB BIOTHERAPEUTICS, INC. (SABS) reported Operating Expenses of $23.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $23.38M, a 140.21% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $20.00M, a 85.64% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $15.77M, a 55.78% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $12.68M, a 12.11% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating expenses for fiscal 2025 was $48.95M, a 10.67% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. operating expenses for fiscal 2024 was $44.23M, a 9.72% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. operating expenses for fiscal 2023 was $40.31M, a 23.68% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. operating expenses for fiscal 2022 was $52.82M, a 28.88% decline from fiscal 2021.
| Period end | Operating Expenses 2 month | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.38M 10-Q · filed 2026-08-06 | $43.38M 10-Q · filed 2026-08-06 | $59.14M derived: sum of 3 quarters · filed 2026-08-06 | $71.82M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $20.00M 10-Q · filed 2026-05-12 | $35.77M derived: sum of 2 quarters · filed 2026-05-12 | $48.45M derived: sum of 3 quarters · filed 2026-05-12 | $58.18M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $15.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $28.45M derived: sum of 2 quarters · filed 2026-03-09 | $38.18M derived: sum of 3 quarters · filed 2026-08-06 | $48.95M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $12.68M 10-Q · filed 2025-11-14 | $22.41M derived: sum of 2 quarters · filed 2026-08-06 | $33.18M 10-Q · filed 2025-11-14 | $43.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $9.73M 10-Q · filed 2026-08-06 | $9.73M 10-Q · filed 2025-08-07 | $20.50M 10-Q · filed 2026-08-06 | $20.50M 10-Q · filed 2025-08-07 | $30.63M derived: sum of 3 quarters · filed 2026-08-06 | $41.94M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $10.77M 10-Q · filed 2026-05-12 | $20.90M derived: sum of 2 quarters · filed 2026-05-12 | $32.21M derived: sum of 3 quarters · filed 2026-05-12 | $42.67M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $10.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $21.43M derived: sum of 2 quarters · filed 2026-03-09 | $31.90M derived: sum of 3 quarters · filed 2026-03-09 | $44.23M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $11.31M 10-Q · filed 2025-11-14 | $21.77M derived: sum of 2 quarters · filed 2025-11-14 | $34.11M 10-Q · filed 2025-11-14 | $53.29M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $10.46M 10-Q · filed 2025-08-07 | $22.80M 10-Q · filed 2025-08-07 | $41.98M derived: sum of 3 quarters · filed 2025-08-07 | $48.57M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $12.34M 10-Q · filed 2025-05-09 | $31.51M derived: sum of 2 quarters · filed 2025-05-09 | $38.10M derived: sum of 3 quarters · filed 2025-05-09 | $44.67M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | $19.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $25.77M derived: sum of 2 quarters · filed 2025-03-31 | $32.33M derived: sum of 3 quarters · filed 2025-03-31 | $40.31M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $6.59M 10-Q · filed 2024-11-06 | $13.15M derived: sum of 2 quarters · filed 2024-11-06 | $21.14M 10-Q · filed 2024-11-06 | $31.16M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $6.56M 10-Q · filed 2024-08-08 | $14.55M 10-Q · filed 2024-08-08 | $24.57M derived: sum of 3 quarters · filed 2024-08-08 | $35.96M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $7.98M 10-Q · filed 2024-05-20 | $18.00M derived: sum of 2 quarters · filed 2024-05-20 | $29.40M derived: sum of 3 quarters · filed 2024-05-20 | $42.29M derived: sum of 4 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | $10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $21.42M derived: sum of 2 quarters · filed 2024-03-29 | $34.31M derived: sum of 3 quarters · filed 2024-03-29 | $52.82M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $11.40M 10-Q · filed 2023-11-13 | $24.29M derived: sum of 2 quarters · filed 2023-11-13 | $42.80M 10-Q · filed 2023-11-13 | $61.20M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $12.89M 10-Q · filed 2023-08-21 | $31.40M 10-Q · filed 2023-08-21 | $49.81M derived: sum of 3 quarters · filed 2023-08-21 | $68.48M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | $18.51M 10-Q · filed 2023-05-15 | $36.91M derived: sum of 2 quarters · filed 2023-05-15 | $55.58M derived: sum of 3 quarters · filed 2023-05-15 | $76.67M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $18.40M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $37.07M derived: sum of 2 quarters · filed 2023-04-28 | $58.16M derived: sum of 3 quarters · filed 2023-04-28 | $74.27M 10-K/A · filed 2023-04-28 | ||||
| 2021-09-30 | $18.67M 10-Q · filed 2022-11-14 | $335.55K 10-Q · filed 2021-11-22 | $39.75M derived: sum of 2 quarters · filed 2022-11-14 | $55.87M 10-Q · filed 2022-11-14 | $704.01K 10-Q · filed 2021-11-22 | |||
| 2021-06-30 | $21.08M 10-Q · filed 2022-08-10 | $256.85K 10-Q · filed 2021-08-09 | $37.20M 10-Q · filed 2022-08-10 | $368.46K 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $16.11M 10-Q · filed 2022-05-12 | $111.61K 10-Q · filed 2021-05-21 | ||||||
| 2020-12-31 | $9.00K 10-K · filed 2021-04-02 | $34.68M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |